Status:
COMPLETED
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of...
Eligibility Criteria
Inclusion
- Signed informed consent, postmenopausal females, histological or cytological confirmed oestrogene and/or progesterone (PgR) receptor positive breast cancer, local recurrence or metastasis
Exclusion
- Previous systemic endocrine therapy for advanced or recurrent disease; prior fulvestrant therapy
- Premenopausal women
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
514 Patients enrolled
Trial Details
Trial ID
NCT00256698
Start Date
January 1 2004
End Date
February 1 2012
Last Update
August 1 2012
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brampton, Canada
2
Research Site
Halifax, Canada
3
Research Site
Kingston, Canada
4
Research Site
Ontario, Canada